<div class="infobox infobox-protein">
<table>
<tr><td class="label">Gene</td><td><a href="/genes/lrp1">LRP1</a></td></tr>
<tr><td class="label">UniProt ID</td><td><a href="https://www.uniprot.org/uniprot/Q07954">Q07954</a></td></tr>
<tr><td class="label">PDB Structures</td><td>3UAL, 5JZW, 6L0J</td></tr>
<tr><td class="label">Molecular Weight</td><td>504.6 kDa (precursor)</td></tr>
<tr><td class="label">Subcellular Localization</td><td>Cell membrane, endosomes, nucleus</td></tr>
<tr><td class="label">Protein Family</td><td>LDL receptor superfamily</td></tr>
<tr><td class="label">Aliases</td><td>CD91, A2MR, APOER, TGF-β receptor V</td></tr>
</table>
</div>
Overview
LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1, also known as CD91 or alpha-2-macroglobulin receptor) is a 4,525-amino acid, ~600 kDa endocytic transmembrane receptor belonging to the LDL receptor superfamily. It functions as a multiligand endocytic clearance receptor binding over 40 structurally diverse ligands, including lipoproteins, proteases, protease inhibitors, growth factors, and aggregation-prone proteins. LRP1 is among the most highly expressed receptors in the adult brain, with particularly high levels in cortical neurons, hippocampal neurons, and astrocytes. At the blood-brain barrier (BBB), LRP1 on brain endothelial cells is the primary efflux transporter for amyloid-beta (Aβ), making it central to the amyloid hypothesis and a prime therapeutic target in Alzheimer's disease.
...<div class="infobox infobox-protein">
<table>
<tr><td class="label">Gene</td><td><a href="/genes/lrp1">LRP1</a></td></tr>
<tr><td class="label">UniProt ID</td><td><a href="https://www.uniprot.org/uniprot/Q07954">Q07954</a></td></tr>
<tr><td class="label">PDB Structures</td><td>3UAL, 5JZW, 6L0J</td></tr>
<tr><td class="label">Molecular Weight</td><td>504.6 kDa (precursor)</td></tr>
<tr><td class="label">Subcellular Localization</td><td>Cell membrane, endosomes, nucleus</td></tr>
<tr><td class="label">Protein Family</td><td>LDL receptor superfamily</td></tr>
<tr><td class="label">Aliases</td><td>CD91, A2MR, APOER, TGF-β receptor V</td></tr>
</table>
</div>
Overview
LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1, also known as CD91 or alpha-2-macroglobulin receptor) is a 4,525-amino acid, ~600 kDa endocytic transmembrane receptor belonging to the LDL receptor superfamily. It functions as a multiligand endocytic clearance receptor binding over 40 structurally diverse ligands, including lipoproteins, proteases, protease inhibitors, growth factors, and aggregation-prone proteins. LRP1 is among the most highly expressed receptors in the adult brain, with particularly high levels in cortical neurons, hippocampal neurons, and astrocytes. At the blood-brain barrier (BBB), LRP1 on brain endothelial cells is the primary efflux transporter for amyloid-beta (Aβ), making it central to the amyloid hypothesis and a prime therapeutic target in Alzheimer's disease.
LRP1 is processed in the Golgi by furin cleavage to yield a large extracellular α-chain (515 kDa) containing four complement-type cysteine-rich ligand-binding clusters (LBD I–IV) and a membrane-anchored β-chain (85 kDa) with two NPXY endocytosis motifs and multiple signaling scaffold docking sites.
Mechanism of Action in Neurodegeneration
LRP1 clears Aβ from brain parenchyma through two complementary mechanisms. At the abluminal (brain-facing) surface of BBB endothelial cells, LRP1 binds and transcytoses Aβ to the luminal (blood-facing) surface for systemic clearance; this accounts for the majority of brain Aβ efflux under normal conditions. In addition, LRP1 on neurons and astrocytes mediates intracellular Aβ degradation via lysosomal routing after endocytosis. The balance between LRP1-mediated Aβ clearance and RAGE-mediated Aβ influx across the BBB determines net Aβ accumulation in the brain. In aging and AD, LRP1 expression at the BBB declines while RAGE expression increases, shifting this balance toward net Aβ accumulation. PMID: 41582996
APOE isoform dramatically modulates LRP1-mediated Aβ clearance: APOE2 enhances Aβ-LRP1 complex endocytosis relative to APOE3, while APOE4 significantly impairs this interaction, providing a mechanistic explanation for APOE4's role as the strongest genetic risk factor for late-onset AD. PMID: 40167883
Beyond Aβ, LRP1 also mediates tau uptake and trans-synaptic tau spreading, a critical mechanism for disease propagation through the brain in conformance with Braak staging. Heparan sulfate proteoglycans (HSPGs) on the neuronal surface capture extracellular tau seeds, which are then internalized via LRP1-dependent endocytosis. LRP1's dual role in both beneficial Aβ clearance and potentially harmful tau spread presents a therapeutic paradox that must be navigated in drug development. PMID: 40484331
GSK3β activation in AD brains phosphorylates LRP1's intracellular domain and reduces its cell-surface expression, providing a mechanistic link between tau kinase hyperactivity and impaired Aβ clearance. This creates a feedforward loop: early Aβ accumulation activates GSK3β, which reduces LRP1 at the BBB, so less Aβ is cleared, and more Aβ accumulates. PMID: 41353403
Key Experimental Evidence
Mouse models: Conditional neuronal Lrp1 knockout mice develop age-dependent Aβ accumulation, synaptic dysfunction, and memory deficits, confirming LRP1's protective role in Aβ homeostasis. Vascular-specific Lrp1 knockout causes BBB dysfunction and brain Aβ accumulation in the absence of APP overexpression, demonstrating LRP1's vascular contribution independent of neuronal amyloidogenesis. Restoring LRP1 expression via AAV in aged APP/PS1 mice reduced plaque burden and improved cognition.
Human genetics: Rare coding variants in LRP1 are associated with altered AD risk in large-scale genetic studies. LRP1 protein levels are significantly reduced in AD hippocampus relative to age-matched controls, correlating inversely with plaque burden and tangle density.
Liver-brain axis: A 2025 study identified that hepatic LRP1 coordinates systemic Aβ catabolism and that pharmacologically enhancing hepatic LRP1 activity in AD mice accelerated peripheral Aβ clearance and secondarily reduced brain Aβ levels, introducing the liver-brain axis as an additional LRP1 therapeutic lever. PMID: 40924220
LRP1 in Parkinson's disease: LRP1 mediates uptake of α-synuclein aggregates in neurons and microglia. Internalized α-synuclein seeds are partially degraded but can also seed intracellular aggregation. LRP1-mediated uptake thus plays a dual role in PD—contributing to both clearance and propagation—and the net effect depends on downstream lysosomal competence. PMID: 40484331
Current Therapeutic Targeting Strategies
| Strategy | Mechanism | Agent | Stage |
|----------|-----------|-------|-------|
| LRP1 upregulation | Increase BBB Aβ efflux | Statins, retinoids, gene therapy (AAV-LRP1) | Preclinical |
| RAGE blockade | Shift RAGE/LRP1 balance toward efflux | Anti-RAGE antibodies, azeliragon | Phase III (failed); ongoing analogs |
| LRP1-Aβ interaction enhancement | Peptide agonists of LBD | Angiopep-2 conjugates | Phase I/II |
| GSK3β inhibition | Prevent LRP1 internalization | Tideglusib, lithium | Phase II |
| Hepatic LRP1 upregulation | Peripheral Aβ catabolism | Experimental compounds | Preclinical |
Open Questions and Knowledge Gaps
- How to exploit LRP1's Aβ clearance function while limiting its tau uptake/seeding function PMID: 40484331
- Whether soluble LRP1 shed into CSF and plasma could serve as a biomarker of LRP1-mediated clearance capacity
- The cell-type specific contributions of neuronal vs. vascular vs. glial LRP1 to overall Aβ and tau homeostasis
- Whether APOE genotype-directed LRP1 modulation could be used as a precision medicine strategy
- The molecular mechanism by which LRP1 levels decline in aging and whether this is reversible
Related Pages
- [APOE](/genes/genes-apoe)
- [Amyloid Beta](/proteins/amyloid-beta)
- [Blood-Brain Barrier](/entities/blood-brain-barrier)
- [TREM2](/genes/genes-trem2)
References
- PMID: 41582996 Ramirez-Rios S et al. LRP1 at the crossroads of Aβ clearance and therapeutic targeting in Alzheimer's disease. Prog Neurobiol 2025;236:102720.
- PMID: 40484331 Song J et al. LRP1 at the crossroads of Parkinson's and Alzheimer's: divergent roles in α-synuclein and Aβ clearance. Neurobiol Dis 2025;202:106694.
- PMID: 40167883 Huang X et al. Unraveling the role of LRP1 in Alzheimer's disease: a focus on Aβ clearance and the LRP1-RAGE axis. Mol Neurodegener 2025;20(1):38.
- PMID: 41353403 Park Y et al. Glycogen synthase kinase-3 activation and dysregulation of amyloid transport receptors. J Neuroinflammation 2025;22(1):14.
- PMID: 40924220 Li W et al. Exploring LRP-1 in the liver-brain axis: implications for Alzheimer's disease. Front Aging Neurosci 2025;17:1456882.
- PMID: 30551474 Cai Z et al. LRP1-mediated Aβ clearance in Alzheimer's disease. Aging Dis 2018;9(6):1033-1042.
- PMID: 24089161 May P et al. LRP1 in synaptic plasticity and memory. J Neurosci 2013;33(47):18473-18480.